California State Teachers Retirement System grew its stake in NewLink Genetics Corp (NASDAQ:NLNK) by 28.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 45,768 shares of the biotechnology company’s stock after buying an additional 10,208 shares during the period. California State Teachers Retirement System’s holdings in NewLink Genetics were worth $371,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of NLNK. State Street Corp increased its position in NewLink Genetics by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 4,630 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in NewLink Genetics by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares in the last quarter. Ameriprise Financial Inc. increased its position in NewLink Genetics by 207.1% in the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock worth $3,176,000 after buying an additional 210,360 shares in the last quarter. TD Asset Management Inc. purchased a new stake in NewLink Genetics in the third quarter worth about $256,000. Finally, Stifel Financial Corp purchased a new stake in NewLink Genetics in the third quarter worth about $402,000. Institutional investors and hedge funds own 65.05% of the company’s stock.
A number of analysts have commented on NLNK shares. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. Cantor Fitzgerald set a $26.00 price target on NewLink Genetics and gave the stock a “buy” rating in a research report on Monday, January 8th. Bank of America cut NewLink Genetics from a “buy” rating to a “neutral” rating in a research report on Friday. Stifel Nicolaus restated a “buy” rating and issued a $21.00 price target (down previously from $25.00) on shares of NewLink Genetics in a research report on Friday, March 2nd. Finally, Jefferies Group cut NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $20.17.
NASDAQ NLNK opened at $4.20 on Monday. The stock has a market capitalization of $156.06, a PE ratio of -1.83 and a beta of 1.22. NewLink Genetics Corp has a twelve month low of $3.95 and a twelve month high of $20.47.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.32. The firm had revenue of $10.10 million during the quarter, compared to analyst estimates of $2.72 million. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. research analysts forecast that NewLink Genetics Corp will post -2.35 EPS for the current year.
TRADEMARK VIOLATION WARNING: “California State Teachers Retirement System Has $371,000 Holdings in NewLink Genetics Corp (NLNK)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/california-state-teachers-retirement-system-has-371000-holdings-in-newlink-genetics-corp-nlnk.html.
NewLink Genetics Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.